Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft standard: determination of chromatographic purity by… — submissions

The 5 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-004/2
Series
Public comment period
Version
1.0
Published
30 Jun 2023
Last reviewed
30 Jun 2023
Next review
30 Jun 2024
Identifier
10.71829/cei.cp.4
Certainty
Not rated
Cycle
2023 Q2
Window
28 Apr 2023 – 28 May 2023
Status
Closed
Submissions
5

§2Submissions and responses

5 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Wilhelmina Quaresma, PharmD, BCPS Regulatory affairs, generic medicines sector
DRAFT-RP-HPLC-PURI/005 received 02 May 2023

Nothing in the standard addresses transfer of the method between laboratories

The respondent states that determinations under this standard will be performed by different laboratories on the same material and that without transfer criteria their results are not comparable.

The respondent proposes a transfer protocol with acceptance criteria for inter-laboratory agreement.

Declared interest. Employed by an analytical laboratory that performs contract testing for suppliers, including at least one supplier named in the Institute's assessment set.
Secretariat responseAccepted in part06 Jun 2023

The secretariat accepts this submission in part. Acceptance criteria for agreement between laboratories are added. A full transfer protocol is not, because transfer is a quality-system activity rather than a determination and the series does not address quality systems.

The standard now states the maximum difference between laboratories analysing the same sample at which results are treated as agreeing, and requires that a comparison across laboratories state whether that criterion was met.

Dr Quentin Zimmerthal, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-RP-HPLC-PURI/001 received 14 May 2023

The standard should require documented operator competence

The respondent states that the determination described requires judgement, particularly at the integration step, and that a competence requirement would improve consistency more than any change to the criteria.

The respondent proposes that conformance be conditional on documented operator training.

Declared interest. Has used a compound in the class under assessment under prescription. Declared at the Institute's request; the Institute regards a lived-experience declaration as an interest and not as a disqualification.
Secretariat responseNot accepted11 Jun 2023

The secretariat does not accept this submission. Operator competence is a quality-system matter governed by accreditation requirements the Institute does not administer and cannot verify.

The standard states performance and remains silent on competence. Where judgement affects the result, as at the integration step, the standard requires the judgement to be recorded rather than the operator to be qualified, which is the part the Institute can check from a report. The submission remains published in full.

Brigitta Grünbaum-Sowande, PharmD, PhD University teaching hospital, department of endocrinology
DRAFT-RP-HPLC-PURI/002 received 19 May 2023

The same concept is given three different names in one document

The draft refers to the same quantity as a response rate, a responder proportion and a categorical outcome in different sections. The respondent, who works in health-technology assessment, states that a reader cannot tell whether the three refer to one thing or to three.

The respondent proposes that the glossary term be used at every occurrence and that the glossary entry be linked at first use in each section rather than only at first use in the document.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted27 Jun 2023

The secretariat accepts this submission. The variation was stylistic and its cost to the reader exceeds any benefit.

A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.

Dr Theodora Trelawney, MSc (Regulatory Affairs) Public-sector clinical trials unit
DRAFT-RP-HPLC-PURI/004 received 24 May 2023

The document set should be published in translation

The respondent notes that the assessments concern compounds supplied internationally and that publishing only in English restricts access to the assessment to readers who work in it.

The respondent proposes machine translation of the document set as an interim measure, with human review of the certainty language.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseNot accepted21 Jun 2023

The secretariat does not accept this submission, and records that the underlying point is sound and that the proposed remedy is the difficulty.

A translation whose certainty language has drifted is a different assessment carrying the Institute's name, and the Institute cannot review translations it does not have the capacity to review. The documents remain in English. The submission is published in full because the access problem it identifies is real and unresolved.

Dr Eamon Sandringham-Adu, MD, FRCPsych University department of clinical biochemistry · industry submission
DRAFT-RP-HPLC-PURI/003 received 27 May 2023

The additional determinations required would materially increase release testing cost

The submission is made on behalf of a manufacturer. It states that the draft adds two determinations to those in existing compendial practice, and estimates the additional analytical burden per batch.

The submission does not dispute the analytical reasoning and asks that one of the two be made conditional rather than universal.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted in part04 Jun 2023

The secretariat accepts this submission in part. One determination is made conditional on a stated risk factor. The other is retained because the evidence supplied by the respondent does not bear on whether it is necessary, only on what it costs.

One of the two determinations is now required only where the stated risk factor is present, with the factor defined in the scope, and the other is retained as a universal requirement with the reasoning stated. The submission is identified as an industry submission.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.